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Design -Retrospective analysis of patients' notes to identify items of management costing money; prospective costing of these items. The Medical Research Council acute myeloblastic leukaemia 9 trial was used to identify the amount and distribution of these costs when either one or two courses of induction treatment were required to obtain complete remission. These findings were then extrapolated to four published international controlled trials using similarly intense treatment and in which the number of courses of treatment required for complete remission was stated, to compare British costs for treatment with idarubicin and daunorubicin, both in combination with cytarabine.
Setting-Leukaemia unit, Royal Marsden
Hospital, London. Subjects-Data on 10 patients receiving intensive induction treatment for acute myeloblastic leukaemia were used to identify 160 items of cost in four broad groups: general (including accommodation), diagnostic, supportive treatment, and cytotoxic chemotherapy. One newly treated patient was prospectively assessed over one month, including a time and motion study, to cost these items; then costs for 268 patients from the MRC trial receiving moderate induction chemotherapy including daunorubicin were assessed, and costs for treatment of 522 patients in the four international studies comparing daunorubicin with idarubicin were analysed.
Main outcome measures-Cost effectiveness was measured as the overall cost to obtain complete remission in untreated patients with acute myeloblastic leukaemia after treatment with idarubicin or daunorubicin.
Results-The 160 costed items were measured for their sensitivity in varying the total cost oftreatment, this being assessed within Britain in other district general and private hospitals to measure the extremes of cost of these items. Overall, idarubicin, although more expensive, showed a substantial saving (£1477 per patient) in total hospital costs, more than offsetting the increased cost (£6O7) of the new treatment, an overall saving of £870 per patient (5%). Conclusion-Approaches modelling cost effectiveness may be an essential part of planning new programmes of treatment in the future. This method can be used to estimate the cost effectiveness of the treatments in different environments and countries where costs may vary widely.
Introduction
After the publication of the government's white paper Working for Patients there has been widespread debate on the economic aspects of health care policy. Although in a broad economic analysis total costs and benefits for the whole national economy and for individual patients should be considered, at present only costs and effectiveness within the NHS can be assessed, and it is these that this paper considers.
Improvements 
Discussion
At present it is not possible within Britain to look at the cost benefit of a treatment programme, taking into account all the benefits to the individual and society such as income, taxes, pensions, salvage medicine, and, of course, inevitable death from some cause. This paper therefore did not look at cost-benefit but only costing and cost effectiveness, with the relatively simple end point of complete remission.
The economic analysis shows that overall costs are relatively insensitive to an increase in the cost of cytotoxic chemotherapy. The cost of treatment with idarubicin is on average 127% higher than that with daunorubicin. On the null hypothesis of no difference in efficacy between the two anthracyclines this would result in a projected increase of 3 6% in overall costs. In fact, because of the improvement in efficacy the overall costs are likely to be reduced by 5 1%, a result that might otherwise be achieved by, say, a 10% reduction in hospital accommodation costs or a 20% reduction in the cost of supportive treatment.
The comparisons of cost effectiveness reported in this study were based on the assumption that all costs are variable. It is important to realise this as although there may be savings to a clinical unit that "buys" bed days from its hospital, the hospital overall would not enjoy any economic benefit unless the available bed was used for another patient. This is because accommodation costs are wholly or partly fixed: one empty bed will not produce savings in heat, light, etc, and it is unlikely to lead to a reduction in staffing in the short term. This is also true of the diagnostic department. Most of its costs consist of staffing, equipment, maintenance, and capital charges. These costs will not change until the demand has fallen to a level at which it is possible, for example, to save a staff post or eliminate a machine.
Medical economic analysis is a fairly new concept but one that is assuming growing importance as aging populations and increasingly sophisticated medical approaches place even more demands on health care budgets. New products will certainly be evaluated not just for clinical but also for economic advantages. In future, preregistration studies may well have to have an economic element built into their protocols, but as the present study has shown, it is possible retrospectively to assess the cost effectiveness ofa particular treatment. Certainly such a retrospective approach has its limitations, but it may well be a useful adjunct to planned prospective randomised studies with evaluation of cost effectiveness as an integral part of the investigation. In addition, this method of analysis has the flexibility to allow evaluation of studies in different environments or even other countries where factors such as labour costs may have a profound effect.
